| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | November 18, 2025 |
| Accession Number: | 0001213900-25-106799 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | November 18, 2025 |
| Accession Number: | 0001213900-25-106799 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
6-K - NewcelX Ltd. (0001783036) (Filer)
6-K - NewcelX Ltd. (0001783036) (Filer)
6-K - NewcelX Ltd. (0001783036) (Filer)
ZURICH, Jan. 12, 2026 /PRNewswire/ -- NewcelX Ltd. (NASDAQ:NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today reported the results of an international collaborative research study investigating advanced biomaterial strategies to support the delivery and function of stem cell–derived islets for the treatment of Type 1 Diabetes. The peer reviewed study, published in Diabetology, a journal dedicated to diabetes research, conducted in collaboration with research groups from the University of Technology Sydney, the University of Wisconsin–Madison, Monash University, the Queensland University of Technology, and the Australia
ZURICH and NESS ZIONA, Israel, Jan. 5, 2026 /PRNewswire/ -- NewcelX Ltd. (NASDAQ:NCEL) ("NewcelX"), a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Dr. Julien Boisdron, MD, a seasoned diabetes expert with extensive experience in Swiss big pharma leadership to its Scientific Advisory Board ("SAB"). Dr. Boisdron brings more than two decades of global leadership in diabetes care. He currently serves as Chief Medical Officer for a major Swiss-based multinational large cap ph
Publication in key market advances NewcelX's global IP strategy across Asia and supports the Company's expanding position in neurology and metabolic diseases ZURICH, Dec. 11, 2025 /PRNewswire/ -- NewcelX Ltd. (NASDAQ:NCEL), a next-generation biotechnology company developing advanced cell-therapy and neuroscience-driven therapeutics, today announced the publication of a major international patent application in China covering a new class of quinazoline, benzothiazine, and benzoxazine derivatives (DOXA) for the treatment of neurological diseases. This publication marks an import
ZURICH and NESS ZIONA, Israel, Jan. 5, 2026 /PRNewswire/ -- NewcelX Ltd. (NASDAQ:NCEL) ("NewcelX"), a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Dr. Julien Boisdron, MD, a seasoned diabetes expert with extensive experience in Swiss big pharma leadership to its Scientific Advisory Board ("SAB"). Dr. Boisdron brings more than two decades of global leadership in diabetes care. He currently serves as Chief Medical Officer for a major Swiss-based multinational large cap ph
ZURICH and NESS ZIONA, Israel, Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd. (NASDAQ:NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Prof. Jeremy Shefner, MD, PhD, to the Company's Scientific Advisory Board ("SAB"). Prof. Shefner is a highly respected neurologist specializing in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders. He serves as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute in Phoenix, Arizona — an internationally recognized leader in the treatment and